ArticleBiomaterials research2025
Multifaceted Microneedle Patch: A One-Stop Solution to Combat Multitype Wound Infections.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research advances in microneedle-exosome delivery systems for the treatment of multisystem diseases.Regenerative therapy · 2026Review
- AI-Guided 4D Printing of Carnivorous Plants-Inspired Microneedles for Accelerated Wound Healing.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Exosome-Biomaterial Platforms for Diabetic Skin Infections: Microenvironment Remodeling, Responsive Delivery, and Clinical Translation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial-infected wounds impose a substantial burden worldwide, with polymicrobial infections exacerbating the complexity of healing through dysregulated pH environments and gelatinase-mediated matrix degradation. Herein, we developed a microenvironment-responsive microneedle (MN) patch utilizing a "dynamic warning-graded intervention" strategy. The patch incorporates (a) a bromothymol blue-based pH visual warning system that detects acid-base changes during both acute and chronic infections, (b) a gelatin methacryloyl and exosome matrix material that enables enzyme-triggered release of human bone marrow mesenchymal stem cell-derived exosomes, responding to pathological gelatinase for spatiotemporal drug delivery, and (c) triple therapeutic payloads [hemostasis (halloysite nanotubes)/antibacterial and anti-inflammatory (antimicrobial peptides)/scar reduction (salvianolic acid B)]. In vitro validation demonstrated a bacterial clearance rate exceeding 95% against methicillin-resistant
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.